Sanofi-Genzyme BioVentures

About The Fund

Sanofi-Genzyme BioVentures is a Corporate Venture Capital fund based in Cambridge, Massachusetts, focused on the field of life sciences. As an important player in healthcare, Sanofi is engaged in the research, development, manufacturing, and marketing of innovative therapeutic solutions. The fund actively supports areas such as diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health, and enzyme products. It represents the merged identity of two prominent groups, Sanofi and Synthlabo, which came together in 1999, and later, Aventis, formed through the merger of Rhône-Poulenc and Hoechst Marion Roussel. Post the 2004 acquisition of Aventis by Sanofi-Synthelabo, the new entity sanofi-aventis emerged, which later simplified its brand to Sanofi in 2011, commanding presence in over 100 countries globally. Sanofi-Genzyme BioVentures holds a specialized focus on merging early-stage transformational science and technology, particularly in the areas of biotech and digital health. Their investment approach encapsulates a wide range of stages in the private company lifecycle, from Seed to Series B and beyond. The fund is skilled at leading financings and functioning on boards, maximizing long-term value while actively seeking new innovations in healthcare. With a minimum investment threshold of $7,500,000 and a maximum of $17,500,000, they invest in top-tier companies transforming medicine and patient care. Notably, their portfolio includes commitments in biotech firms like Eligo Bioscience, Granite Bio, Muna Therapeutics, NodThera, OMass Therapeutics, QurAlis, T-Therapeutics, and Therini Bio. Digital Health investments encompass Aetion, Carbon Health, Click Tx, Empatica, Medisafe, Nucleai, and Omada. Its investments and board roles have also reached Lava Therapeutics, highlighting a diverse and innovation-driven portfolio strategy, aiming to invest in the pioneers behind the miracles of science dedicated to improving human health.